Howland Capital Management LLC Purchases 11,251 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Howland Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 72.9% in the first quarter, now holding 26,688 shares valued at approximately $16.9 million.
• Several analysts have issued new price targets for Regeneron, with the average target price set at $837.61 and ratings ranging from "sell" to "strong buy."
• Regeneron reported a quarterly earnings miss, with earnings per share at $8.22, below the estimated $8.83, and a revenue of $3.03 billion, which was below expectations.

Howland Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 72.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,688 shares of the biopharmaceutical company's stock after purchasing an additional 11,251 shares during the period. Howland Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $16,926,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Marietta Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $4,915,000. Rhenman & Partners Asset Management AB lifted its holdings in Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after purchasing an additional 4,457 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after purchasing an additional 955 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a "neutral" rating in a report on Friday, July 11th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $837.61.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $545.46 on Friday. The firm's 50 day simple moving average is $538.64 and its 200 day simple moving average is $604.99. The firm has a market capitalization of $58.89 billion, a price-to-earnings ratio of 13.89, a P/E/G ratio of 2.08 and a beta of 0.33. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $9.55 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.